The advent of gene therapy, grounded in recombinant DNA technology, has reached a critical juncture with regulatory approvals by the EMA and FDA. At the heart of this innovation lies plasmid DNA, essential for therapeutic development and mRNA-based vaccines. Advanced plasmid sequencing techniques, such as Sanger sequencing, enable precise genetic analysis, driving unprecedented medical advancements. This convergence of curiosity and science not only propels gene therapy but also underscores the limitless potential of biomedicine, promising revolutionary treatments for previously untreatable conditions.

Downstream process is fine tuned to recover the soluble fraction of plasmidic DNA, whereas the genomic DNA, proteins polysaccharides and total RNA from E. coli cells are precipitated and removed by depth filtration.

A plasmid is a circular double-stranded DNA molecule that exists separately from the chromosomal DNA within a cell.

The utilization of plasmid DNA in the production of viral vectors for gene therapy represents a critical advancement in medical biotechnology.

Lentiviruses and adeno-associated viruses (AAV) require specific plasmids for their production, which ensure efficient vector generation and safe delivery of the gene of interest (GOI).

Many people first became familiar with the term “mRNA” when COVID-19 vaccines were rolled out. In the simplest terms, mRNA, which stands for messenger ribonucleic acid, is a genetic material that instructs the cells to make specific proteins.